Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Want to cut your energy bills? Here’s how five experts are doing it 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
BRISBANE, Calif., March 08, 2016 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced the receipt of positive coverage from TRICARE® National Insurance for AlloMap®.
As a part of the military health system, TRICARE is the health care program for active and returned service members and their dependents. TRICARE has over 9 million lives covered in their programs. This positive coverage decision applies to all TRICARE regions and offers retroactive coverage of AlloMap from February 2015 onwards.
“The positive coverage decision for AlloMap by TRICARE is deserved by individuals in the military and their beneficiaries who are heart transplant patients,” said Jim Yee, MD PhD, Chief Medical Officer. “Our military service population who are covered by TRICARE will now have the same access that is available through non-military health plans. We hope that this decision will ensure that patients covered by TRICARE will no longer have barriers to access AlloMap testing services.”
About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. The company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure, its next-generation sequencing–based test to detect donor-derived cell-free DNA after transplantation. For more information, please visit: www.CareDx.com
Media Contacts – CareDx Molly Martell, Senior Director, Marketing T: +1 415-728-6307 E: [email protected] Media Contacts - Investor Jamar Ismail, Vice President Westwicke Partners, LLC T: +1 650-996-8777 E: [email protected]
